US HB4244 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 5-0)
Status: Introduced on September 9 2019 - 25% progression, died in committee
Action: 2019-09-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 9 2019 - 25% progression, died in committee
Action: 2019-09-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, and for other purposes.
Title
MAGIC Act Market Access for Generic Insulin Competition
Sponsors
| Rep. Mike Kelly [R-PA] | Rep. Scott Perry [R-PA] | Rep. Glenn Thompson [R-PA] | Rep. Brian Fitzpatrick [R-PA] |
| Rep. Fred Keller [R-PA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-09-10 | House | Referred to the Subcommittee on Health. |
| 2019-09-09 | House | Referred to the House Committee on Energy and Commerce. |
| 2019-09-09 | House | Introduced in House |
Subjects
Competition and antitrust
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Manufacturing
Prescription drugs
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Manufacturing
Prescription drugs
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/4244/all-info |
| Text | https://www.congress.gov/116/bills/hr4244/BILLS-116hr4244ih.pdf |
